title: Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.
abstract: Up to 30% of patients with attention-deficit hyperactivity disorder (ADHD) treated with psychostimulants discontinue the treatment because of intolerance or lack of therapeutic response. Therapeutic alternatives are needed for such patients. In the present case series, we study the effectiveness of reboxetine over a period of 6 months in a sample of 14 children diagnosed with ADHD according to DSM-IV-TR criteria, who had responded only partially or had presented poor tolerance to conventional treatment with methylphenidate. Clinical efficacy was evaluated through the application of the 18-item Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) and the Clinical Global Impressions-Global Improvement Scale (CGI-I). Percentages of responders (ADHD-RS ≥ 25%) and improvers (CGI-I absolute value < 4) were 90.9 and 72.7%, respectively. No serious side-effects were observed during treatment, the most frequent effects being headaches and insomnia. The initial findings of our study show that reboxetine may constitute an effective tool for long-term treatment of children with ADHD who present poor response or poor tolerance to initial treatment with methylphenidate.
authors: Department of Psychiatry, Infanta Leonor Hospital, Madrid, Spain. fjquinterog@salud.madrid.org
authors: Javier
authors: J
authors: Quintero
authors: Francisco
authors: F
authors: López-Muñoz
authors: Cecilio
authors: C
authors: Alamo
authors: Mercedes
authors: M
authors: Loro
authors: Natalia
authors: N
authors: García-Campos
mesh_terms: D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D000077593:Reboxetine; D012720:Severity of Illness Index
chemical_list: D000697:Central Nervous System Stimulants; D009025:Morpholines; D008774:Methylphenidate; D000077593:Reboxetine